ARTICLE | Top Story
Xolair amendment slated for 4Q02
November 1, 2001 8:00 AM UTC
Tanox (TNOX) partners Genentech (DNA) and Novartis (NVS; SWX:NOVN) plan to submit an amendment to the FDA in the fourth quarter of 2002 for their BLA for Xolair omalizumab to treat allergic asthma in ...